fludarabine has been researched along with paclitaxel in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Faure, P; Madelaine-Chambrin, I; Piquet-Sevrin, V | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; North, L; Pate, O; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, AH; Younes, A | 1 |
| Bassan, R; Di Gaetano, N; Erba, E; Golay, J; Introna, M; Rambaldi, A; Xiao, Y | 1 |
| Abbasi, MR; Sarta, C; Sparano, JA; Wiernik, PH | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Tiongson, LP; Younes, A | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Baba, T; Hamanishi, J; Kang, HS; Kharma, B; Konishi, I; Mandai, M; Matsumura, N; Murphy, SK; Yamaguchi, K; Yamanoi, K; Yoshioka, Y | 1 |
| Anghel, AG; Badea, M; Bleotu, C; Bordei, E; Crantea, G; Gavrilă, RI; Grecu, A; Grumezescu, AM; Holban, AM; Jercan, DA; Nicolae, BC; Tchinda, K; Vochiţoaia, GC; Voicu, G | 1 |
| Baba, J; Ichikawa, K; Igarashi, N; Ishikawa, D; Kagamu, H; Kondo, R; Koshio, J; Koya, T; Miura, S; Nakata, K; Narita, I; Nozaki, K; Okajima, M; Saida, Y; Sato, K; Shoji, S; Tanaka, J; Tanaka, T; Watanabe, S; Yoshizawa, H | 1 |
1 review(s) available for fludarabine and paclitaxel
| Article | Year |
|---|---|
[Current therapeutic methods in onco-hematology].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cladribine; Docetaxel; Humans; Keratolytic Agents; Leukemia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tretinoin; Vidarabine | 1996 |
3 trial(s) available for fludarabine and paclitaxel
| Article | Year |
|---|---|
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Vidarabine | 1997 |
Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Vidarabine | 2003 |
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vidarabine | 2006 |
11 other study(ies) available for fludarabine and paclitaxel
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Northern; Cisplatin; Complement System Proteins; Cytotoxicity Tests, Immunologic; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Idarubicin; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vidarabine | 2001 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine | 2005 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bayes Theorem; Biomarkers, Tumor; Blotting, Western; Carboplatin; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Survival Rate; Tumor Cells, Cultured; Vidarabine | 2013 |
Silica network improve the effect of fludarabine and paclitaxel on HCT8 cell line.
Topics: Biocompatible Materials; Cell Shape; Endothelial Cells; Humans; Microscopy, Electron, Scanning; Paclitaxel; Silicon Dioxide; Spectrophotometry, Infrared; Tumor Cells, Cultured; Vidarabine; X-Ray Diffraction | 2014 |
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
Topics: Adoptive Transfer; Animals; Cisplatin; Cyclophosphamide; Cytotoxins; Deoxycytidine; Drug Resistance; Etoposide; Female; Fibrosarcoma; Gemcitabine; Lymph Nodes; Lymphocyte Depletion; Lymphopenia; Methylcholanthrene; Mice; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Vidarabine; Whole-Body Irradiation | 2015 |